Danaher Corporation vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.7
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
DHR
Clean balance sheet with low leverage (0.4× debt-to-equity).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $250.14 (+42.8%)
22 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
DHR
MRK
33.9×
Trailing P/E
31.5×
19.3×
Forward P/E
11.5×
14.9%
Profit Margin
13.6%
59.0%
Gross Margin
76.6%
7.1%
ROE
—
3.7%
Revenue Growth
4.9%
9.8%
Earnings Growth
—
0.99
Beta
0.28
—
Price / Book
—
$124.0B
Market Cap
$277.0B
$175 – $243
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →